NTHI NeOnc Technologies Holdings, Inc.
Company Analysis
Latest News
🟢 NeOnc Technologies Holdings is trading 5.9% up in after-hours trading — cause remains unclear
NeOnc Technologies Holdings is trading 5.9% up at $2.89 after closing the October 12 regular session at $2.73; no clear company-specific catalyst has been...
🟢 NeOnc Technologies Holdings is trading 8% up in pre-market — no clear catalyst identified
NeOnc Technologies Holdings is trading at $3.00, up 7.91%, with no direct catalyst established for its pre-market move. - No company-specific announcement was...
🟢 NeOnc Technologies Holdings is trading 11% up today amid biotech-sector strength, with no direct catalyst confirmed
NeOnc Technologies Holdings is trading at $2.80, up 10.83%; biotech-sector strength is the likeliest context. - At 12:46 p.m. ET on October 9, 2026, no...
🟢 NeOnc Technologies Holdings is trading 5% up amid possible biotech-sector support
NeOnc Technologies Holdings is trading 5.04% up at $2.66 as of 10:45 a.m. ET on October 9, 2026, amid possible support from biotech strength; no direct cause...
🟢 NeOnc Technologies Holdings is trading 7% up in pre-market — no confirmed catalyst identified
NeOnc Technologies Holdings is trading 7.11% higher in pre-market at $2.71 on October 9; no confirmed company announcement dated October 9 explains the move. -...
🔴 NeOnc Technologies Holdings is trading 5.7% down
NeOnc Technologies Holdings is trading at $2.56, down 5.72% during the October 8 session, reversing its reported 8.5% pre-market gain; no clear...
🟢 NeOnc Technologies Holdings is trading 8.5% up in pre-market — no company-specific catalyst identified
NeOnc Technologies Holdings is trading 8.5% higher at $2.94 in pre-market, with no clearly linked company-specific catalyst identified. - The price compares...
🔴 NeOnc Technologies Holdings is trading 11.4% down today amid biotech sector weakness
NeOnc Technologies Holdings is trading at $2.65, down 11.37%, amid biotech-sector weakness. - No new company announcement or clearly linked company-specific...
🔴 NeOnc Technologies Holdings is trading 5% down today amid biotech and broader-market weakness
NeOnc Technologies Holdings is trading 5.01% down at $2.84 amid weakness in biotechnology and broader markets. - The supplied sector context reports XBI down...
🟢 NeOnc Technologies Holdings is trading 5% up today
NeOnc Technologies Holdings is trading 5.14% higher at $3.07, but the specific driver remains unclear. - The price has rebounded after several weaker...
🟢 NeOnc Technologies Holdings is trading 5% up in pre-market
NeOnc Technologies Holdings is trading at $3.14, up +5.02% in pre-market; available coverage identified no company-specific announcement explaining the October...
🟢 NeOnc Technologies Holdings is trading 7.84% up in pre-market; no reported company-specific catalyst
NeOnc Technologies Holdings is trading at $3.30, up 7.84% in pre-market, with no newly reported company-specific announcement explaining the gain. - The...
🔴 NeOnc Technologies Holdings is trading 10% down; catalyst remains unclear
NeOnc Technologies Holdings is trading at $3.05, 10.38% down, with the October 1 decline’s catalyst unclear. - The price compares with the September 30 close...
🔴 NeOnc Technologies Holdings is trading 5% down
NeOnc Technologies Holdings is trading 5.14% lower at $3.23; the available information does not establish a specific cause for the move. - The price is down...
🟢 NeOnc Technologies Holdings is trading 7.2% up in pre-market
NeOnc Technologies Holdings is trading at $3.65, up +7.20% in pre-market, with no verified company-specific explanation for the October 1 rise. - The Nasdaq...
🟢 NeOnc Technologies Holdings is trading 5% up today with no new company catalyst identified
NeOnc Technologies Holdings is trading at $3.47, up 5.15%, with broader technology-market strength potentially supportive. - The Nasdaq Composite is up 0.87%...
🟢 NeOnc Technologies Holdings is trading 6.65% up after scheduling FDA End-of-Phase 1 meeting for NEO212
NeOnc Technologies Holdings is trading 6.65% up at $3.37 after an in-person FDA meeting for NEO212 was scheduled for November 17, 2026. - The company plans to...
🟢 NeOnc Technologies Holdings is trading 6.3% up in pre-market after scheduling an FDA meeting for NEO212
NeOnc Technologies Holdings is trading at $3.36, up 6.33% in pre-market, with the scheduled FDA meeting for NEO212 a plausible catalyst. - The company...
NTHI Schedules End-of-Phase 1 FDA Meeting for Cancer Drug Candidate NEO212
NeOnc Technologies Holdings, Inc. (NTHI) announced it has scheduled an End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its cancer...
🟢 NeOnc Technologies Holdings is trading 7.27% up in pre-market after Roth/MKM initiated coverage with Buy rating
NeOnc Technologies Holdings is trading at $3.54, up 7.27% in pre-market after Roth/MKM initiated coverage on September 24, 2026, with a Buy rating and a $20...